Luvesilocin, also known as RE104 and FT-104, as well as 4-glutaryloxy-N,N-diisopropyltryptamine (4-HO-DiPT O-glutarate or 4-GO-DiPT), is a psychedelic drug of the tryptamine and 4-hydroxytryptamine families which is under development for the treatment of psychiatric disorders. It is taken orally or by subcutaneous injection. The drug is a prodrug ester of 4-HO-DiPT, which acts as a non-selective serotonin receptor agonist including of the serotonin 5-HT2A receptor. Luvesilocin was first described in the literature in 2021. It is under development for the treatment of postpartum depression and treatment-resistant depression. As of September 2025, the drug has reached phase 2 clinical trials. A phase 3 trial is planned for 2026.
Use and effects
The effects of luvesilocin have been clinically studied. It was evaluated at doses of 5 to 40 mg (equivalent to ~4–32 mg 4-HO-DiPT) by subcutaneous injection in this study. The drug was specifically assessed in terms of modified Drug Effects Questionnaire (DEQ) ratings, Mystical Experience Questionnaire (MEQ) ratings, and adverse effects. The mean duration of the psychedelic experience after administration of luvesilocin at a dose of 30 mg was found to be 3.6 hours.
Interactions
Pharmacology
Pharmacodynamics Luvesilocin is a prodrug that is metabolized into 4-HO-DiPT. This metabolite is an analogue of the neurotransmitter serotonin and acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor. Activation of the serotonin 5-HT2A receptor is thought to be specifically responsible for the hallucinogenic effects of serotonergic psychedelics. 4-HO-DiPT produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. In drug discrimination tests, 4-HO-DiPT fully substituted for the psychedelic drug DOM, with 5-fold lower potency than DOM and 2-fold lower potency than psilocin (4-HO-DMT). The drug activates basolateral amygdala (BLA) interneurons via the serotonin 5-HT2A receptor to enhance GABAergic inhibition of principal neurons in the BLA, which may mediate an anxiolytic effect of suppression of learned fear (fear extinction) in rodents.
Pharmacokinetics Given by subcutaneous injection, the elimination half-life of luvesilocin is 0.43 to 0.64 hours and of 4-HO-DiPT is 2.7 to 4.1 hours. The mean duration with this route at the employed dose was 3.6 hours.
Chemistry
Synthesis The chemical synthesis of luvesilocin has been described.
Analogues Analogues of luvesilocin include 4-HO-DiPT (iprocin), 4-AcO-DiPT (ipracetin), 4-PrO-DiPT, 4-AcO-DMT (psilacetin), 4-PrO-DMT, and 4-GO-DMT (RE-109), among others.
History Luvesilocin was first described in the literature in 2021.
Society and culture
Names Luvesilocin is the generic name of the drug and its INNTooltip International Nonproprietary Name. It is also known by its developmental code names RE104 or RE-104 and FT104 or FT-104.
Legal status
Canada Luvesilocin is not a controlled substance in Canada as of 2025.
United States Luvesilocin is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
Research Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders. As of September 2025, it has reached phase 2 clinical trials for these indications. A phase 3 trial is planned for 2026. The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).
See also Substituted tryptamine List of investigational hallucinogens and entactogens Bretisilocin (5-fluoro-MET; GM-2505) CT-4201, EB-002, and MSP-1014
References
External links Luvesilocin (RE-104) - AdisInsight Luvesilocin - Isomer Design